Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
ACELYRIN, INC. (SLRN)
NASDAQ:SLRN
Holding SLRN?
Track your performance easily
SLRN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.36 - $8.89
Previous Close$4.55
Volume182.93K
Average Volume (3M)676.61K
Market Cap
$456.48M
Enterprise Value-$99.33M
Total Cash (Recent Filing)$562.37M
Total Debt (Recent Filing)$6.56M
Price to Earnings (P/E)―
Beta1.48
Next Earnings
Mar 27, 2025EPS Estimate
-$0.85Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.68
Shares Outstanding100,325,569
10 Day Avg. Volume503,332
30 Day Avg. Volume676,612
Standard Deviation0.24
R-Squared0.10
Alpha-0.07
Financial Highlights & Ratios
Price to Book (P/B)0.84
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.31
Forecast
1Y Price Target
$12.25Price Target Upside169.23% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
ACELYRIN, INC. News
PremiumCompany Announcements
ACELYRIN Faces CFO Resignation and Trial Setback
PremiumCompany Announcements
ACELYRIN, INC. Advances Key Drug Developments
Bulls Say, Bears Say
Bulls Say
Financial Stability3Q24 cash and equivalents provide a runway through mid-2027+.
Market PotentialUveitis could be a meaningful opportunity for izo, with a potential to capture ~30% of the patient population and peak revenues of ~$700MM.
Regulatory ProgressPositive progress toward lonig regulatory program in TED, with alignment with the FDA on a proposed Ph3 pivotal design.
Bears Say
Clinical TrialsThe company has not confirmed which dose it plans to evaluate in Phase 3, indicating ongoing optimization for a narrow therapeutic window.
Product PipelineAcelyrin announced the de-prioritization of izokibep in hidradenitis suppurativa (HS) and psoriatic arthritis (PsA).
Research And DevelopmentAcelyrin will also halt further development of early-stage asset SLRN-517.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
SLRN FAQ
What was ACELYRIN, INC.’s price range in the past 12 months?
ACELYRIN, INC. lowest stock price was $3.36 and its highest was $8.88 in the past 12 months.
What is ACELYRIN, INC.’s market cap?
Currently, no data Available
When is ACELYRIN, INC.’s upcoming earnings report date?
ACELYRIN, INC.’s upcoming earnings report date is Mar 27, 2025 which is in 96 days.
How were ACELYRIN, INC.’s earnings last quarter?
ACELYRIN, INC. released its earnings results on Nov 13, 2024. The company reported -$0.49 earnings per share for the quarter, beating the consensus estimate of -$0.799 by $0.309.
Is ACELYRIN, INC. overvalued?
According to Wall Street analysts ACELYRIN, INC.’s price is currently Undervalued.
Does ACELYRIN, INC. pay dividends?
ACELYRIN, INC. does not currently pay dividends.
What is ACELYRIN, INC.’s EPS estimate?
ACELYRIN, INC.’s EPS estimate is -$0.85.
How many shares outstanding does ACELYRIN, INC. have?
ACELYRIN, INC. has 100,325,570 shares outstanding.
What happened to ACELYRIN, INC.’s price movement after its last earnings report?
ACELYRIN, INC. reported an EPS of -$0.49 in its last earnings report, beating expectations of -$0.799. Following the earnings report the stock price went down -13.712%.
Which hedge fund is a major shareholder of ACELYRIN, INC.?
Among the largest hedge funds holding ACELYRIN, INC.’s share is Woodline Partners LP. It holds ACELYRIN, INC.’s shares valued at 2M.
---
ACELYRIN, INC. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.25 (169.23% Upside)
$12.25 (169.23% Upside)
Hedge Fund Trend
Decreased
By 1.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.1%
Last 30 Days ▼ 2.7%
Last 30 Days ▼ 2.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.45%
12-Months-Change
Fundamentals
Return on Equity
-41.95%
Trailing 12-Months
Asset Growth
-22.76%
Trailing 12-Months
Company Description
ACELYRIN, INC.
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against insulin-like growth factor 1 receptor, which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease; and SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. The company was incorporated in 2020 and is headquartered in Agoura Hills, California.
---
SLRN Earnings Call
Q3 2024
0:00 / 0:00
---
SLRN Stock 12 Month Forecast
Average Price Target
$12.25
▲(169.23% Upside)
Technical Analysis
Best Analysts Covering SLRN
1 Year
1 Year Success Rate
1/13 ratings generated profit
1 Year Average Return
-40.85%
assigned a buy rating last month
Copying Yasmeen Rahimi's trades and holding each position for 1 Year would result in 7.69% of your transactions generating a profit, with an average return of -40.85% per trade.
---